In light of their well-described pro-metastatic roles in other aspects of malignancy in breast cancer [38,39,40,41,42,43], these findings call for the careful consideration of the therapeutic effects of inhibitors targeting STAT3 and p65 in the clinic. Here, STAT3 is linked to breast carcinoma.